Evidence map›Paper›PMID 41649527›Full record

Observational studyPediatric nephrology (Berlin, Germany)2026

Single relapse at ≥ 0.5 mg/kg alternate-day prednisone predicts course of childhood nephrotic syndrome.

Abigail A Lazar, Elena Zion, Evgenia Gurevich, Yael Borovitz, Meital Keidar, Roxana Cleper, Orly Haskin, Hadas Alfandary, Daniella Levy-Erez, Shelly Levi and 3 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Abigail A LazarSchneider Children's Medical Center of Israel, Petah Tikvah, Israel. AbbyLazar@gmail.com.
Elena ZionBoston Children's Hospital, Boston, MA, USA.
Evgenia GurevichClalit Medical Health Services, Tel Aviv, Israel.
Yael BorovitzSchneider Children's Medical Center of Israel, Petah Tikvah, Israel.
Meital KeidarWolfson Medical Center, Holon, Israel.
Roxana CleperDana-Dwek Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel.
Orly HaskinSchneider Children's Medical Center of Israel, Petah Tikvah, Israel.
Hadas AlfandarySchneider Children's Medical Center of Israel, Petah Tikvah, Israel.
Daniella Levy-ErezSchneider Children's Medical Center of Israel, Petah Tikvah, Israel.
Shelly LeviSchneider Children's Medical Center of Israel, Petah Tikvah, Israel.
Gilad HamdaniSchneider Children's Medical Center of Israel, Petah Tikvah, Israel.
Daniel LandauSchneider Children's Medical Center of Israel, Petah Tikvah, Israel.
Amit DaganSchneider Children's Medical Center of Israel, Petah Tikvah, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAround half of children with steroid-sensitive nephrotic syndrome are eventually diagnosed with frequently relapsing or steroid-dependent disease. To minimize steroid toxicity, guidelines usually recommend switching these patients to steroid-sparing agents. Unfortunately, morbidity from steroids can be irreversible, and patients may suffer even after steroid discontinuation.

methodsThis is a multicenter observational study of children with steroid-sensitive nephrotic syndrome. We compared patients that were eventually diagnosed with frequently relapsing/steroid-dependent nephrotic syndrome with those with non/infrequently relapsing nephrotic syndrome. Additionally, we compared the risk of being diagnosed with frequently relapsing/steroid-dependent nephrotic syndrome, between patients with relapse on a prednisone dose equivalent of ≥ 0.5 mg/kg/every other day versus patients with no relapses above this cutoff.

resultsPatients who relapsed during induction were more likely to develop frequently relapsing/steroid-dependent nephrotic syndrome. Patients with ≥ 1 relapse on prednisone equivalent of ≥ 0.5 mg/kg/every other day were 33 times more likely to develop frequently relapsing/steroid-dependent nephrotic syndrome (p value < 0.001).

conclusionsPatients with one relapse on prednisone equivalent of ≥ 0.5 mg/kg/every other day are at high risk of an eventual diagnosis of frequently relapsing/steroid-dependent nephrotic syndrome. Further studies are needed to determine whether a single relapse above this cutoff is reliable enough to enable clinicians to switch patients to steroid-sparing agents before meeting formal criteria for frequently relapsing/steroid-dependent disease.

Indexed as

GlucocorticoidsNephrotic SyndromePrednisoneAdolescentChildChild, PreschoolDrug Administration ScheduleFemaleHumansInfantMaleRecurrenceGlucocorticoidsPrednisoneDisease progressionHigh-dose relapsesIdiopathic nephrotic syndromePediatric kidney diseasePediatric nephrologySteroid responsivenessSteroid-sparing agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.